Cargando…

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

Detalles Bibliográficos
Autores principales:	Muppidi, Srikanth, Guptill, Jeffrey T, Jacob, Saiju, Li, Yingkai, Farrugia, Maria E, Guidon, Amanda C, Tavee, Jinny O, Kaminski, Henry, Howard, James F, Cutter, Gary, Wiendl, Heinz, Maas, Matthew B, Illa, Isabel, Mantegazza, Renato, Murai, Hiroyuki, Utsugisawa, Kimiaki, Nowak, Richard J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837033/ https://www.ncbi.nlm.nih.gov/pubmed/33212055 http://dx.doi.org/10.1016/S1474-4422(20)30413-0

Ejemplares similares

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
por: Jacob, Saiju, et al.
Publicado: (2020)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study
por: Jacob, Saiju, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Insights into the Classification of Myasthenia Gravis
por: Akaishi, Tetsuya, et al.
Publicado: (2014)

Three Types of Striational Antibodies in Myasthenia Gravis
por: Suzuki, Shigeaki, et al.
Publicado: (2011)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

Utilization of MG‐ADL in myasthenia gravis clinical research and care [Image: see text]
por: Muppidi, Srikanth, et al.
Publicado: (2022)

Response to treatment of myasthenia gravis according to clinical subtype
por: Akaishi, Tetsuya, et al.
Publicado: (2016)

Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
por: Nishimoto, Yoshinori, et al.
Publicado: (2011)

Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study
por: Konno, Shingo, et al.
Publicado: (2015)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
por: Mantegazza, Renato, et al.
Publicado: (2021)

Early fast‐acting treatment strategy against generalized myasthenia gravis
por: Utsugisawa, Kimiaki, et al.
Publicado: (2017)

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
por: Guptill, Jeffrey T., et al.
Publicado: (2023)

Novel Immunotherapies for Myasthenia Gravis
por: Nair, Sruthi S, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
por: Dewilde, Sarah, et al.
Publicado: (2023)

Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study
por: McPherson, Tarrant, et al.
Publicado: (2020)

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study
por: Nagane, Yuriko, et al.
Publicado: (2017)

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis
por: Guptill, Jeffrey T., et al.
Publicado: (2015)

Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021)

Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis
por: Harris, Linda, et al.
Publicado: (2019)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study
por: Suzuki, Yasushi, et al.
Publicado: (2011)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
por: Regnault, Antoine, et al.
Publicado: (2023)

Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
por: Gable, Karissa L., et al.
Publicado: (2020)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

Correction to: Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
por: Regnault, Antoine, et al.
Publicado: (2023)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study
por: Nowak, Richard J., et al.
Publicado: (2020)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)
por: Berrih-Aknin, Sonia, et al.
Publicado: (2021)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China
por: Huang, Xin, et al.
Publicado: (2018)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lnc8opnjhe63kof3bd0ajiqpl2